Rankings
Publications
Search Publications
Cited-by Search
Sources
Publishers
Scholars
Scholars
Top Cited Scholars
Organizations
About
Scilit
About Us
Advisory Board
Data Sources
Career
Support / Contact
User Guide
Publisher User
Search Function
Rankings Function
API Resource
Scilit Knowledge
Metrics
Scilit Recognitions
Publications Classification
Media
News
Blog
Login
Register
Home
Publications
Supplementary Figure 2 from A PD-L1/CD3 Bispecific Antibody Enhances the Antitumor Effects of Regorafenib against Colon Cancer
Home
Publications
Supplementary Figure 2 from A PD-L1/CD3 Bispecific Antibody Enhances the Antitumor Effects of Regorafenib against Colon Cancer
Supplementary Figure 2 from A PD-L1/CD3 Bispecific Antibody Enhances the Antitumor Effects of Regorafenib against Colon Cancer
Authors:
IO
Izuchukwu F. Okpalanwaka
Izuchukwu F. Okpalanwaka
Elizabeth A. Daugherity
Elizabeth A. Daugherity
AM
Amanda L. McCormick
Amanda L. McCormick
TA
Trevor S. Anderson
Trevor S. Anderson
SS
Savanna L. Smith
Savanna L. Smith
CL
Caryn Lawrence
Caryn Lawrence
DA
Duke Appiah
Duke Appiah
DL
Devin B. Lowe
Devin B. Lowe
Article Alert
Citation Alert
Add to Library
Cite
Download
Share
Download
Open Access
Publisher website
Google Scholar
1 August 2025
other
Published by
American Association for Cancer Research (AACR)
DOI:
10.1158/1535-7163.29760650
Abstract
Supplementary Figure 2 details PD-L1 expression is not observably altered following REG exposure.
Keywords
SUPPLEMENTARY FIGURE
BISPECIFIC ANTIBODY
ANTIBODY ENHANCES
ANTITUMOR EFFECTS
COLON CANCER
REG EXPOSURE
CANCER SUPPLEMENTARY
FIGURE
OBSERVABLY ALTERED
DETAILS
Related articles
Scroll to top